Last checked at 26 Jun 2020 11:45
26 June 2020
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 11.00 a.m. today, all resolutions were duly passed.
The Company has prepared a new presentation for shareholders and a copy will be available on the Company's website later today.
For further information:
Proteome Sciences plc | |
Dr Ian Pike, Interim Chief Executive Officer & Chief Scientific Officer
Richard Dennis, Chief Commercial Officer | Tel: +44 (0)20 7043 2116 |
Allenby Capital Limited (AIM Nominated Adviser & Broker) | |
John Depasquale / Jeremy Porter | Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.